Key Takeaways Bristol Myers' shares fell below the 50-day SMA amid a 4.7% monthly decline.Generic erosion in key drugs and high debt continue to drag BMY's top line.Despite strong growth drugs like Opdivo and Reblozyl, 2025 EPS guidance was cut.Shares of Bristol Myers (BMY) continue to lose momentum in 2025. In fact, the stock lost 4.7% in a month against the industry’s gain of 4.8%. Consequently, the stock slipped below its 50-day simple moving average (SMA) on Oct. 2. The stock closed at $45.11 on Oct. 2, ...